4-二苯基甲基-1-(2,3-环氧丙基)哌嗪 | 111452-72-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-二苯基甲基-1-(2,3-环氧丙基)哌嗪
• 英文名称: 1-(diphenylmethyl)-4-(2,3-epoxypropyl)piperazine
• 英文别名: 1-(diphenylmethyl)-4-(2-oxiranylmethyl)piperazine；1-(diphenylmethyl)-4-(1-(2,3-epoxy)propyl)piperazine；1-benzhydryl-4-(oxiranylmethyl)piperazine；1-benzhydryl-4-oxiran-2-ylmethyl-piperazine；4-(2,3-epoxypropyl)-1-diphenylmethylpiperazine；1-diphenylmethyl-4-oxiranylmethylpiperazine；1-(Diphenylmethyl)-4-[(oxiran-2-yl)methyl]piperazine；1-benzhydryl-4-(oxiran-2-ylmethyl)piperazine
• CAS: 111452-72-3
• 化学式: C₂₀H₂₄N₂O
• 分子量: 308.423
• InChiKey: PNBNIKKSFYNIFB-UHFFFAOYSA-N

物化性质

• 熔点：
  99-102 °C
• 沸点：
  423.9±35.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  19
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-二苯基甲基-1-(2,3-环氧丙基)哌嗪 生成 6-hydroxy-α-[(4-diphenylmethyl-1-piperazinyl)methyl]-9H-purine-9-ethanol
  参考文献：
  名称：

  OTT, HANS

  摘要：

  DOI：
• 作为产物：
  描述：

  2-hydroxy-3-[4-diphenylmethyl-1-piperazinyl]propyl chloride 在 四丁基溴化铵 、 potassium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 反应 2.5h， 以0.68 mmol的产率得到4-二苯基甲基-1-(2,3-环氧丙基)哌嗪
  参考文献：
  名称：

  Al(OTf)₃-Mediated Epoxide Ring-Opening Reactions: Toward Piperazine-Derived Physiologically Active Products

  摘要：

  Al(OTf)(3) is a good catalyst for the ring opening of epoxides, forming beta-amino alcohols bearing the piperazine motif. Two different strategies were examined, where the glycidyl ether resided on one-half of the molecule or the other, allowing insight into a best-case approach for the ring-opening step. Each half of the molecule contained an heteroatom that could be used either to attach the glycidyl moiety or as the nucleophile in the ring-opening reaction, for the same set of reagents, allowing this approach.

  DOI：

  10.1021/jo9020437

文献信息

• Compounds enhancing antitumor activity of other cytotoxic agents
  申请人：Pfizer Inc

  公开号：US06130217A1

  公开（公告）日：2000-10-10

  This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).

  这项发明涉及某些杂环化合物及其药用可接受的盐，这些化合物对于使多药耐药肿瘤细胞对抗癌药物和多药耐药形式的疟疾、结核病、利什曼病和阿米巴痢疾对化疗药物具有敏感性是有用的。这些化合物及其药用可接受的盐还是人类MDR1基因编码的P-糖蛋白的活性药物转运能力的抑制剂，以及来自真核和原核生物（例如，来自疟原虫的pfmdr，以及小鼠mdr1和mdr3基因产物）的某些其他相关的ATP结合盒转运蛋白的抑制剂。
• Anticancer agents
  申请人：Kaneko Noboru

  公开号：US06683083B1

  公开（公告）日：2004-01-27

  Disclosed herein is a method for suppressing the growth of cancer cells in a mammal in need of such treatment comprising administering to said mammal a cancer cell suppressing amount of a diphenylmethylpiperazine represented by the following general formula [1]: wherein R represents: or a pharmaceutically acceptable salt thereof. Compared with conventional anticancer agents, these agents are less toxic and exert an excellent carcinostatic effect on various solid cancers. Moreover, these anticancer agents inhibit the proliferation of fibroblasts, which makes them efficacious against pulmonary fibrosis and proliferative keloid lesions.

  本文揭示了一种抑制哺乳动物体内癌细胞生长的方法，包括向该哺乳动物体内投与下列一般式［1］所代表的二苯甲基哌嗪的癌细胞抑制量，其中R代表：或其药用可接受的盐。与传统的抗癌药物相比，这些药物毒性较小，并对各种实体癌症具有出色的抑癌作用。此外，这些抗癌药物抑制成纤维细胞的增殖，使其对肺纤维化和增生性瘢痕病变具有疗效。
• DIPHENYLMETHYL PIPERAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION USING SAME
  申请人：Kaneko Noboru

  公开号：US20140296253A1

  公开（公告）日：2014-10-02

  The present invention provides: a novel compound which has a useful pharmacological action for treating heart failure or shock without increasing heart rate; and a pharmaceutical composition using the same. The present invention relates to a diphenylmethyl piperazine derivative represented by general formula (I) (In the formula, R 1 is a hydrogen atom or a hydroxy group. R 2 is a hydrogen atom, a halogen atom, a hydroxy group, an alkyl group having one to five carbon atoms, or an alkoxyl group having one to five carbon atoms, excluding the case where R 1 is a hydroxy group and R 2 is a chlorine atom.) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.

  本发明提供了一种新型化合物，具有治疗心力衰竭或休克的有用药理作用，而不会增加心率；以及使用该化合物的药物组合物。本发明涉及一种由通式（I）表示的二苯甲基哌嗪衍生物（在该式中，R1是氢原子或羟基。R2是氢原子、卤素原子、羟基、具有一至五个碳原子的烷基或具有一至五个碳原子的烷氧基，不包括R1是羟基且R2是氯原子的情况。）或其药学上可接受的盐，以及含有该化合物的药物组合物。
• Purine derivatives, medicaments containing them and methods of treating
  申请人：Sandoz Ltd.

  公开号：US04849423A1

  公开（公告）日：1989-07-18

  The compounds of formula I, ##STR1## in free form or in salt form have cardiotonic and antiarrhythmic activity. They may be used as medicaments. They are obtained by means of appropriate 3-amino-2-hydroxy-propylation of purines.

  公式I的化合物，##STR1##以自由形式或盐形式具有强心和抗心律失常活性。它们可以用作药物。它们是通过适当的3-氨基-2-羟基-丙基化嘌呤获得的。
• Synthesis and biological activity of 4-(diphenylmethyl)-.alpha.-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds
  作者：Ila Sircar、Steve J. Haleen、Sandra E. Burke、Hubert Barth

  DOI：10.1021/jm00101a022

  日期：1992.11

  one-tenth the potency of compound 1. Both compounds 1 and 15 demonstrated direct inotropic and vasodilatory effects when administered iv in anesthetized dogs, although the vasodilatory activity was more pronounced with compound 15 than 1 and DPI compound. Compound 1 lacks the CN moiety which is a key structural requirement in DPI for positive inotropic activity. The synthesis, in vitro, and in vivo evaluations

  合成了一系列的4-（二苯甲基）-α-[（4-喹啉基氧基）甲基] -1-管嗪乙醇及其密切相关的化合物，并评估了离体灌流大鼠和豚鼠心脏的心脏和血管活性。与豚鼠心脏相比，化合物1在大鼠心脏中产生的正性肌力作用更大，这种现象在原型药物DPI 201-106中也观察到。化合物15产生的肌力作用为化合物1的十分之一。当在麻醉犬中静脉给药时，化合物1和15都表现出直接的肌力作用和血管舒张作用，尽管化合物15的血管舒张活性比1和DPI化合物更为明显。化合物1缺少CN部分，这是DPI中正性肌力活性的关键结构要求。体外合成